Lab Information
Waqqas Afif (MD/MSc)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Inflammatory bowel disease • Crohn's disease • ulcerative colitis • biologic medications • therapeutic drug monitoringResearch Interests
My research focuses on the safety and efficiency of biologic medications in the treatment of IBD. I am interested in the use of therapeutic drug monitoring to optimize the treatment of IBD patients on biologic medications.Team Members
| Name | Position |
|---|
Latest Publications
- Sealey, D. C., Ho, K. F., Zhou, Z. C., Clark, M., Feagan, B. G., Panaccione, R., Steinhart, A. H., Bolshtyansky, E., Williamson, M. & Afif, W. (2025). Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data. Canadian journal of gastroenterology & hepatology, vol. 2025, p. 5713315.
- Targownik, L., Afif, W., Singh, S., Siffledeen, J., Ma, C., McHugh, K., Charbonneau, J. & Rioux, L.-C. (2025). Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 21-30.
- Zhen, J., Simoneau, M., Sharma, P., Germain, P., Watier-Levesque, P., Othman, A., Marshall, J. K., Afif, W. & Narula, N. (2024). Acceptability, feasibility, and impact of the MyGut digital health platform in the monitoring and management of inflammatory bowel disease. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 423-430.
- Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
- Pedicelli, A. & Afif, W. (2024). In active ulcerative colitis, risankizumab induced and maintained remission. Annals of internal medicine, vol. 177, p. JC127.
- Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
- Birck, M. G., Lukusa, L., Choquette, D., Boire, G., Maksymowych, W. P., Singh, H., Afif, W. & Bernatsky, S. (2024). Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data. BMC rheumatology, vol. 8, p. 47.
- Seow, C. H., Marshall, J. K., Stewart, E., Pettengell, C., Ward, R. & Afif, W. (2024). The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 290-298.
- Jairath, V., Afif, W., Bressler, B., Pope, J. E., Selchen, D., Targownik, L. E. & Panaccione, R. (2024). Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 282-289.
- Bacsur, P., Wetwittayakhlang, P., Resál, T., Földi, E., Vasas, B., Farkas, B., Rutka, M., Bessissow, T., Afif, W., Bálint, A., Fábián, A., Bor, R., Szepes, Z., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241239606.
See also
